Microbial Protein Binding to gC1qR Drives PLA2G1B-Induced CD4 T-Cell Anergy.
CD4 T cell
HCV
HIV
PLA2G1B
gC1qR
infectious disease
porphyromonas gingivalis
staphylococcus aureus
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
11
2021
accepted:
28
02
2022
entrez:
8
4
2022
pubmed:
9
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
The origin of the impaired CD4 T-cell response and immunodeficiency of HIV-infected patients is still only partially understood. We recently demonstrated that PLA2G1B phospholipase synergizes with the HIV gp41 envelope protein in HIV viremic plasma to induce large abnormal membrane microdomains (aMMDs) that trap and inactivate physiological receptors, such as those for IL-7. However, the mechanism of regulation of PLA2G1B activity by the cofactor gp41 is not known. Here, we developed an assay to directly follow PLA2G1B enzymatic activity on CD4 T-cell membranes. We demonstrated that gp41 directly binds to PLA2G1B and increases PLA2G1B enzymatic activity on CD4 membrane. Furthermore, we show that the conserved 3S sequence of gp41, known to bind to the innate sensor gC1qR, increases PLA2G1B activity in a gC1qR-dependent manner using gC1qR KO cells. The critical role of the 3S motif and gC1qR in the inhibition of CD4 T-cell function by the PLA2G1B/cofactor system in HIV-infected patients led us to screen additional microbial proteins for 3S-like motifs and to study other proteins known to bind to the gC1qR to further investigate the role of the PLA2G1B/cofactor system in other infectious diseases and carcinogenesis. We have thus extended the PLA2G1B/cofactor system to HCV and
Identifiants
pubmed: 35392090
doi: 10.3389/fimmu.2022.824746
pmc: PMC8981723
doi:
Substances chimiques
Carrier Proteins
0
Interleukin-7
0
Membrane Glycoproteins
0
Receptors, Complement
0
complement 1q receptor
0
Group IB Phospholipases A2
EC 3.1.1.4
PLA2G1B protein, human
EC 3.1.1.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
824746Informations de copyright
Copyright © 2022 Pothlichet, Meola, Bugault, Jeammet, Savitt, Ghebrehiwet, Touqui, Pouletty, Fiore, Sauvanet and Thèze.
Déclaration de conflit d'intérêts
JT is cofounder and CSO of DIACCURATE, a spin-off of the Institut Pasteur. JP, AM, FB, and LJ are, or were, employees of DIACCURATE. PP was employed by company Truffle Capital. BG receives royalties from the sale of anti-gC1qR antibodies and gC1qR detection assay kit. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Infect Immun. 2000 Apr;68(4):2061-8
pubmed: 10722602
Infect Immun. 2006 Aug;74(8):4418-23
pubmed: 16861627
Clin Infect Dis. 1998 May;26(5):1179-81
pubmed: 9597249
Gut. 2013 Dec;62(12):1764-70
pubmed: 22990306
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10981-6
pubmed: 16046540
BMC Infect Dis. 2016 Sep 29;16(1):529
pubmed: 27686579
Clin Nutr. 2021 Apr;40(4):1897-1904
pubmed: 33023764
PLoS Pathog. 2014 Feb 13;10(2):e1003871
pubmed: 24550724
J Clin Microbiol. 2005 Sep;43(9):4455-9
pubmed: 16145091
J Microbiol Immunol Infect. 2016 Feb;49(1):119-22
pubmed: 24529567
Cell. 2014 Apr 10;157(2):407-419
pubmed: 24725407
Lancet Infect Dis. 2011 Feb;11(2):142-51
pubmed: 21272794
PLoS Pathog. 2010 Jul 01;6:e1000975
pubmed: 20617170
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):525-534
pubmed: 32944895
Semin Immunol. 2019 Oct;45:101338
pubmed: 31744753
Cancer Cell. 2020 Mar 16;37(3):289-307.e9
pubmed: 32183949
Clin Oral Investig. 2014 Sep;18(7):1835-43
pubmed: 24352581
J Clin Invest. 2020 Jun 1;130(6):2872-2887
pubmed: 32436864
Cell Rep. 2019 Jun 11;27(11):3315-3330.e7
pubmed: 31189114
Clin Infect Dis. 2013 Sep;57(5):745-55
pubmed: 23696512
EcoSal Plus. 2018 Feb;8(1):
pubmed: 29424333
Mol Immunol. 2016 Jun;74:18-26
pubmed: 27111569
Cancers (Basel). 2020 Aug 18;12(8):
pubmed: 32824786
Gut. 2018 Jan;67(1):120-127
pubmed: 27742762
PLoS Negl Trop Dis. 2021 Mar 18;15(3):e0009272
pubmed: 33735202
J Oral Microbiol. 2017 Jun 21;9(1):1317579
pubmed: 28748027
J Oral Microbiol. 2019 Jan 09;11(1):1563410
pubmed: 30671195
Cell. 2017 Feb 23;168(5):904-915.e10
pubmed: 28235200
Mol Oral Microbiol. 2021 Jun;36(3):172-181
pubmed: 33715305
Medicine (Baltimore). 2016 Dec;95(49):e5541
pubmed: 27930550
Front Immunol. 2020 Nov 30;11:615056
pubmed: 33329610
Annu Rev Biochem. 2008;77:495-520
pubmed: 18405237
PLoS Biol. 2020 Sep 4;18(9):e3000825
pubmed: 32886690
Pathogens. 2020 Nov 13;9(11):
pubmed: 33202751
J Clin Invest. 2000 Nov;106(10):1239-49
pubmed: 11086025
Cell Host Microbe. 2018 Feb 14;23(2):203-214.e5
pubmed: 29398651
Scand J Infect Dis. 1992;24(5):667-72
pubmed: 1465587
Mol Biol Rep. 2021 Jan;48(1):147-156
pubmed: 33289908
Nat Rev Microbiol. 2005 Dec;3(12):948-58
pubmed: 16322743